Skip to content
Trial Eligibility
Menu

5-HTP and Creatine for Depression R33 Phase

NCT05895747

This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .

Summary

This is a three-armed clinical trial examining the effect of 5-hydroxytryptophan and creatine monohydrate as augmenting agents for the treatment of depression. Subjects will be randomized between 5-HTP 100mg BID + creatine 5g daily, 5-HTP 200mg BID + creatine 10g daily, vs double placebo, for 8 weeks. The ability of the interventions to affect biomarkers associated with depression will be assessed using brain phosphorus magnetic resonance spectroscopy, functional connectivity imaging, and plasma serotonin levels.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

  • Major Depressive Disorder

Eligibility basics and study details

Study type
Interventional
Phase
Phase 2
Ages
18 to 65 years
Sex
All
Healthy volunteers
Not accepted
Sponsor
University of Utah
Last updated on ClinicalTrials.gov
August 27, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites

Utah · 1

  • University of Utah Department of Psychiatry · Salt Lake City, UT

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.